Holen Sie sich die Stockscreener-App
10.22
0.20%
0.015
Schlusskurs vom Vortag:
$10.21
Offen:
$10.09
24-Stunden-Volumen:
1.41M
Relative Volume:
0.28
Marktkapitalisierung:
$1.10B
Einnahmen:
$45.97M
Nettoeinkommen (Verlust:
$-508.80M
KGV:
-1.8659
EPS:
-5.48
Netto-Cashflow:
$-382.65M
1W Leistung:
-6.15%
1M Leistung:
-19.00%
6M Leistung:
-15.94%
1J Leistung:
-56.67%
1-Tages-Spanne:
$9.93
$10.24
1-Wochen-Bereich:
$9.82
$11.30
52-Wochen-Spanne:
$5.90
$24.16
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
10.21 | 1.15B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.64 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.07 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.97 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
662.78 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
312.09 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
The Future of Medicine: Investing in Organoid Technology's Biotech Revolution - AInvest
ARK Investment's Confidence in Intellia Therapeutics Drives Analyst Upgrades and Positive Market Sentiment - AInvest
Intellia Therapeutics Inc. Price Targets Raised After ReboundMarket Sentiment Review & Community Consensus Stock Picks - beatles.ru
Intellia (NTLA.O) Sharp Drop: Technical Clues and Market Clusters Point to Pressure - AInvest
Intellia (NTLA.O) Sharp Intraday Drop: Technicals, Order Flow, and Peer Dynamics Signal a Sudden Selloff - AInvest
ARK Investment buys 560K shares of Intellia Therapeutics - MSN
Cathie Wood's ARK Investment Purchases 560K Shares of Intellia Therapeutics - AInvest
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential - MSN
Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN - MSN
Is Intellia Therapeutics Inc. stock a smart retirement pickJuly 2025 Trends & Technical Buy Zone Confirmation - newsyoung.net
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game Changer - TipRanks
Upgrade Alert: Intellia Therapeutics' Time to Shine - AInvest
Intellia Therapeutics Inc. Reversal Rally May Surprise BearsJuly 2025 Big Picture & Long-Term Capital Growth Strategies - newsyoung.net
Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade) (NASDAQ:NTLA) - Seeking Alpha
Is Intellia Therapeutics Inc. stock a buy or sellTrade Analysis Summary & Weekly Chart Analysis and Trade Guides - thegnnews.com
Reversal Confirmed Intellia Therapeutics Inc. Stock Rallies Above MAJuly 2025 Decliners & Reliable Breakout Forecasts - newsyoung.net
Guggenheim Sticks to Its Buy Rating for Intellia Therapeutics (NTLA) - The Globe and Mail
Will Intellia Therapeutics Inc. outperform small cap indexesTrade Entry Report & Fast Moving Stock Trade Plans - mustnews.co.kr
Intellia Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year By Investing.com - Investing.com Australia
Intellia Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year - Investing.com
Guggenheim Maintains Buy Rating for Intellia Therapeutics with $14 Price Target - AInvest
Intellia Therapeutics’ Earnings Call Highlights Progress and Challenges - The Globe and Mail
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game-Changer? - TipRanks
Guggenheim Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $14 - 富途牛牛
Intellia Therapeutics stock price target slashed by Guggenheim to $14 - Investing.com Nigeria
Why Intellia Therapeutics Inc. stock attracts strong analyst attentionEMA/SMA Crossover Stock List - sisaissue.com
Analysts Are Upgrading Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results - Yahoo Finance
Intellia slides after safety concern for Regeneron-partnered gene editing therapy - MSN
Walt Disney To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Intellia Therapeutics: Chardan Capital Keeps Buy Rating, Cuts PT to $60 - AInvest
Will Intellia Therapeutics Inc. Benefit From Broader Market BounceReal Trader Watchlist of Hot Stocks Released - beatles.ru
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript - MSN
Intellia targets 1,200 patients in expanded Phase III ATTR cardiomyopathy trial as enrollment accelerates - MSN
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus - MSN
Citi Maintains Hold Rating on Intellia Therapeutics with $12 Price Target - AInvest
Intellia Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Have Lowered Expectations For Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results - 富途牛牛
Intellia Therapeutics Surpasses Q2 Earnings and Revenue Expectations - AInvest
Wells Fargo Sticks to Their Buy Rating for Intellia Therapeutics (NTLA) - The Globe and Mail
Intellia Therapeutics Reports Q2 2025 Progress and Financials - The Globe and Mail
Wells Fargo Maintains Overweight on Intellia, PT Down to $45 - AInvest
Intellia Therapeutics stock price target lowered to $45 by Wells Fargo - Investing.com Canada
Leerink Partners lowers Intellia Therapeutics stock price target to $41 By Investing.com - Investing.com Canada
Intellia: HC Wainwright Keeps Buy Rating, Lowers PT to $25 from $30. - AInvest
Gene-Editing's Quiet Revolution: Why Intellia Therapeutics Could Redefine Rare Disease Investing - AInvest
INTELLIA THERAPEUTICS, INC. (NTLA) - MSN
Intellia (NTLA) Q2 Revenue Jumps 106% - AOL.com
Intellia Therapeutics' NTLA-2001 in Phase III Development for ATTR-CM: A Promising CRISPR/Cas9 Therapy - AInvest
Intellia Therapeutics Inc (NTLA) Q2 2025 Earnings Call Highlights: Strategic Advancements and Financial Resilience - GuruFocus
Intellia Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Intellia Therapeutics' Momentum in ATTR-CM and HAE Trials: A Catalyst-Driven Path to First-Time Commercial Success - AInvest
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '25 |
Sale |
9.82 |
1,022 |
10,036 |
95,369 |
| Dube Michael P | VP, Chief Accounting Officer |
Jul 02 '25 |
Sale |
9.95 |
2,503 |
24,905 |
57,137 |
| GOODMAN JESSE | Director |
Jun 30 '25 |
Sale |
9.56 |
1,547 |
14,789 |
25,906 |
| GOODMAN JESSE | Director |
Jul 01 '25 |
Sale |
9.23 |
1,547 |
14,279 |
24,359 |
| Bhanji Muna | Director |
Apr 29 '25 |
Sale |
8.50 |
265 |
2,252 |
19,203 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
| Bhanji Muna | Director |
Jan 29 '25 |
Sale |
9.97 |
265 |
2,642 |
19,468 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 03 '25 |
Sale |
12.18 |
1,372 |
16,711 |
45,640 |
| BASTA JAMES | EVP, General Counsel |
Jan 03 '25 |
Sale |
12.18 |
7,074 |
86,161 |
74,497 |
0.91%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):